S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:TNYA

Tenaya Therapeutics - TNYA Competitors

$2.64
+0.11 (+4.35%)
(As of 03/27/2023 04:00 PM ET)
Add
Compare
Today's Range
$2.55
▼
$2.72
50-Day Range
$2.29
▼
$3.59
52-Week Range
$1.64
▼
$14.43
Volume
265,664 shs
Average Volume
378,577 shs
Market Capitalization
$176.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33

TNYA vs. CCCC, ADAP, SRNE, ABOS, FUSN, IVVD, ARYD, FENC, GNFT, and OCGN

Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include C4 Therapeutics (CCCC), Adaptimmune Therapeutics (ADAP), Sorrento Therapeutics (SRNE), Acumen Pharmaceuticals (ABOS), Fusion Pharmaceuticals (FUSN), Invivyd (IVVD), ARYA Sciences Acquisition Corp IV (ARYD), Fennec Pharmaceuticals (FENC), Genfit (GNFT), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry.

Tenaya Therapeutics vs.

C4 Therapeutics (NASDAQ:CCCC) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.

In the previous week, C4 Therapeutics had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 3 mentions for C4 Therapeutics and 1 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.93 beat C4 Therapeutics' score of 0.79 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
C4 Therapeutics Positive
Tenaya Therapeutics Positive

C4 Therapeutics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.

80.3% of C4 Therapeutics shares are held by institutional investors. 14.2% of C4 Therapeutics shares are held by company insiders. Comparatively, 34.2% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

C4 Therapeutics currently has a consensus price target of $15.44, suggesting a potential upside of 342.53%. Tenaya Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 614.29%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than C4 Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C4 Therapeutics
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22
Tenaya Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

C4 Therapeutics received 8 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. However, 63.16% of users gave Tenaya Therapeutics an outperform vote while only 39.22% of users gave C4 Therapeutics an outperform vote.

CompanyUnderperformOutperform
C4 TherapeuticsOutperform Votes
20
39.22%
Underperform Votes
31
60.78%
Tenaya TherapeuticsOutperform Votes
12
63.16%
Underperform Votes
7
36.84%

Tenaya Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4 Therapeutics$31.10 million5.50-$128.18 million-$2.62-1.33
Tenaya TherapeuticsN/AN/A-$123.67 million-$2.79-0.95

Tenaya Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -412.19%. C4 Therapeutics' return on equity of -38.94% beat Tenaya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
C4 Therapeutics -412.19% -38.94% -26.98%
Tenaya Therapeutics N/A -54.20% -47.44%

Summary

Tenaya Therapeutics beats C4 Therapeutics on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNYA vs. The Competition

Export to Excel
MetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$177.85M$2.61B$4.31B$5.85B
Dividend YieldN/A2.23%5.97%4.51%
P/E Ratio-0.952.2294.2912.09
Price / SalesN/A161.143,426.1457.36
Price / CashN/A16.9527.12103.15
Price / Book0.732.614.494.98
Net Income-$123.67M$66.22M$114.18M$190.13M
7 Day Performance1.92%5.20%108.46%2.67%
1 Month Performance-8.75%-0.98%102.38%-4.44%
1 Year Performance-77.07%-24.78%105.99%-17.58%

Tenaya Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CCCC
C4 Therapeutics
2.1451 of 5 stars		$3.61
-9.3%		$15.44
+327.8%		-85.7%$177.07M$31.10M-1.38121Short Interest ↓
ADAP
Adaptimmune Therapeutics
1.7948 of 5 stars		$1.11
-6.7%		$6.75
+508.1%		-47.6%$171.67M$27.15M-1.09494Analyst Report
Short Interest ↑
SRNE
Sorrento Therapeutics
1.8885 of 5 stars		$0.35
-10.2%		$12.50
+3,436.1%		-86.0%$166.81M$60.32M0.00799Analyst Report
Gap Down
ABOS
Acumen Pharmaceuticals
1.9988 of 5 stars		$4.08
+5.2%		$17.67
+333.0%		-23.7%$165.24M$1.44M0.0014Gap Up
FUSN
Fusion Pharmaceuticals
2.1155 of 5 stars		$4.13
+2.7%		$11.25
+172.4%		-47.2%$184.86M$1.46M-2.0783
IVVD
Invivyd
1.6681 of 5 stars		$1.42
-9.6%		$2.00
+40.8%		N/A$154.75MN/A-0.55N/AAnalyst Report
ARYD
ARYA Sciences Acquisition Corp IV
0 of 5 stars		$10.32
+0.2%		N/A+5.2%$198.04MN/A0.003Positive News
FENC
Fennec Pharmaceuticals
1.6771 of 5 stars		$7.57
-5.3%		$14.83
+95.9%		+28.0%$199.92M$170,000.00-9.23N/AHigh Trading Volume
GNFT
Genfit
1.7347 of 5 stars		$4.10
+1.0%		$7.00
+70.6%		-8.4%$204.46M$101.25M0.00122
OCGN
Ocugen
1.6382 of 5 stars		$0.91
-4.2%		$4.80
+427.0%		-73.5%$206.22M$42.62M-2.4056
This page (NASDAQ:TNYA) was last updated on 3/27/2023 by MarketBeat.com Staff